Orion is a Finnish pharmaceutical company that develops, manufactures, and markets human and animal medicines. Its portfolio spans proprietary specialty products—notably in areas such as neurology (including Parkinson’s disease treatments), oncology, and respiratory care—alongside generic drugs and animal health products. It sells through its own organizations in key markets and via partners elsewhere, combining R&D with established Nordic manufacturing.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 354.6 | — | 61.3 | 40.6% |
| Q2 2025 | 416.5 | — | 82.5 | 58.9% |
| Q4 2025 | 695.3 | — | 260.5 | 256.9% |
| Q1 2026 | 417.7 | 17.8% | 90.4 | 47.5% |
| Q2 2026 | 521.6 | 25.2% | 140.2 | 69.9% |
All markets — KeepWinning global stock screener
Other companies on Helsinki: Orion Oyj (ORNAV), SSAB AB (publ) (SSABBH), SSAB AB (publ) (SSABAH), Kesko Oyj (KESKOB), Kesko Oyj (KESKOA), Stora Enso Oyj (STEAV)